{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:31:23Z","timestamp":1793133083723,"version":"4.5.0"},"reference-count":90,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Optimizing the use of antibiotics has become mandatory, particularly for the pediatric population where limited options are currently available. Selecting the dosing strategy may improve overall outcomes and limit the further development of antimicrobial resistance. Time-dependent antibiotics optimize their free concentration above the minimal inhibitory concentration (MIC) when administered by continuous infusion, however evidences from literature are still insufficient to recommend its widespread adoption. The aim of this review is to assess the state-of-the-art of intermittent versus prolonged intravenous administration of antibiotics in children and neonates with bacterial infections. We identified and reviewed relevant literature by searching PubMed, from 1 January 1 2000 to 15 April 2020. We included studies comparing intermittent versus prolonged\/continuous antibiotic infusion, among the pediatric population. Nine relevant articles were selected, including RCTs, prospective and retrospective studies focusing on different infusion strategies of vancomycin, piperacillin\/tazobactam, ceftazidime, cefepime and meropenem in the pediatric population. Prolonged and continuous infusions of antibiotics showed a greater probability of target attainment as compared to intermittent infusion regimens, with generally good clinical outcomes and safety profiles, however its impact in terms on efficacy, feasibility and toxicity is still open, with few studies led on children and adult data not being fully extendable.<\/jats:p>","DOI":"10.3390\/antibiotics9060329","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T13:11:32Z","timestamp":1592399492000},"page":"329","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Optimizing Antibiotic Treatment Strategies for Neonates and Children: Does Implementing Extended or Prolonged Infusion Provide any Advantage?"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1948-2631","authenticated-orcid":false,"given":"Paola","family":"Costenaro","sequence":"first","affiliation":[{"name":"Division of Paediatric Infectious Diseases, Department for Women\u2019s and Children\u2019s Health, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Minotti","sequence":"additional","affiliation":[{"name":"Department for Women\u2019s and Children\u2019s Health, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cuppini","sequence":"additional","affiliation":[{"name":"Department for Women\u2019s and Children\u2019s Health, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0850-8784","authenticated-orcid":false,"given":"Elisa","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Division of Paediatric Infectious Diseases, Department for Women\u2019s and Children\u2019s Health, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Giaquinto","sequence":"additional","affiliation":[{"name":"Division of Paediatric Infectious Diseases, Department for Women\u2019s and Children\u2019s Health, University of Padova, 35128 Padova, Italy"},{"name":"Department for Women\u2019s and Children\u2019s Health, University of Padova, 35128 Padova, Italy"},{"name":"Paediatric Network for Treatment of AIDS (Penta) Foundation, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Don\u00e0","sequence":"additional","affiliation":[{"name":"Division of Paediatric Infectious Diseases, Department for Women\u2019s and Children\u2019s Health, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/cid\/ciu069","article-title":"Treatment of Multidrug-Resistant Gram-Negative Infections in Children","volume":"58","author":"Hsu","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","first-page":"CD008481","article-title":"Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections","volume":"28","author":"Shiu","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e14632","DOI":"10.1097\/MD.0000000000014632","article-title":"Continuous versus intermittent infusions of antibiotics for the treatment of infectious diseases","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous infusion of beta-lactam antibiotics in severe sepsis: A multicenter double-blind, randomized controlled trial","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Yu, Z., Pang, X., Wu, X., Shan, C., and Jiang, S. (2018). Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0201667"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","article-title":"Continuous versus intermittent \u03b2-lactam infusion in severe sepsis: A meta-analysis of individual patient data from randomized trials","volume":"194","author":"Roberts","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","article-title":"Beta-Lactam Infusion in Severe Sepsis (BLISS): A prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis","volume":"42","author":"Sulaiman","year":"2016","journal-title":"Intensive Care Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: A systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1086\/504383","article-title":"The antimicrobial therapy puzzle: Could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?","volume":"42","author":"Pea","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2165\/00003088-200645110-00003","article-title":"Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations","volume":"45","author":"Bartelink","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient-Concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2165\/00003088-200544100-00002","article-title":"Antimicrobial therapy in critically ill patients: A review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability","volume":"44","author":"Pea","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1128\/AAC.40.1.61","article-title":"Serum bactericidal activity of ceftazidime: Continuous infusion versus intermittent injections","volume":"40","author":"Nicolau","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/MCC.0b013e3282e2a98f","article-title":"Continuous infusion of beta-lactams","volume":"13","author":"Mouton","year":"2007","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1592\/phco.26.9.1320","article-title":"Application of antimicrobial pharmacodynamic concepts into clinical practice: Focus on \u03b2-lactam antibiotics-Insights from the Society of Infectious Diseases Pharmacists","volume":"26","author":"Lodise","year":"2006","journal-title":"Pharmacotherapy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.siny.2004.10.004","article-title":"New dosing strategies for antibacterial agents in the neonate","volume":"10","author":"Mouton","year":"2005","journal-title":"Semin. Fetal Neonatal Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1345\/aph.1M717","article-title":"High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients","volume":"44","author":"Moriyama","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1345\/aph.1R216","article-title":"Continuous and extended infusions of beta-lactam antibiotics in the pediatric population","volume":"46","author":"Walker","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/ja.2014.111","article-title":"Glycopeptide antibiotics: Back to the future","volume":"67","author":"Butler","year":"2014","journal-title":"J. Antibiot."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.01674-10","article-title":"Refining vancomycin protein binding estimates: Identification of clinical factors that influence protein binding","volume":"55","author":"Butterfield","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","unstructured":"Taketomo, C.K., and Hodding, J.H.K.D. (2007). Pediatric Dosage Handbook, Lexi-Comp. [14th ed.]."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/17512433.2015.1060124","article-title":"How to use vancomycin optimally in neonates: Remaining questions","volume":"8","author":"Leroux","year":"2015","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/INF.0b013e3181906e40","article-title":"Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate","volume":"28","author":"Frymoyer","year":"2009","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.18773\/austprescr.2017.049","article-title":"Paediatric Injectable Guidelines","volume":"40","author":"Lilley","year":"2017","journal-title":"Aust. Prescr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.burns.2012.07.005","article-title":"Individualised vancomycin doses for paediatric burn patients to achieve PK\/PD targets","volume":"39","author":"Gomez","year":"2013","journal-title":"Burns"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","article-title":"Improved vancomycin dosing in children using area under the curve exposure","volume":"32","author":"Le","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/archdischild-2012-302765","article-title":"Vancomycin continuous infusion in neonates: Dosing optimisation and therapeutic drug monitoring","volume":"98","author":"Zhao","year":"2013","journal-title":"Arch. Dis. Child."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1097\/PCC.0000000000001474","article-title":"Achievement of therapeutic vancomycin exposure with continuous infusion in critically Ill children","volume":"19","author":"Genuini","year":"2018","journal-title":"Pediatr. Crit. Care Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/jac\/dky525","article-title":"Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data","volume":"74","author":"Germovsek","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkr442","article-title":"Continuous versus intermittent infusion of vancomycin for the treatment of gram-positive infections: Systematic review and meta-analysis","volume":"67","author":"Cataldo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1128\/AAC.45.9.2460-2467.2001","article-title":"Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: Prospective multicenter randomized study","volume":"45","author":"Wysocki","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijantimicag.2015.10.019","article-title":"Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis","volume":"47","author":"Hao","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.5546\/aap.2013.e31","article-title":"Continuous infusion of vancomycin in pediatric critical care","volume":"111","author":"Zylbersztajn","year":"2013","journal-title":"Arch. Argent Pediatr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e20182179","DOI":"10.1542\/peds.2018-2179","article-title":"Continuous versus intermittent Vancomycin infusions in infants: A randomized controlled trial","volume":"143","author":"Gwee","year":"2019","journal-title":"Pediatrics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3233\/NPM-15814103","article-title":"Comparison of intermittent versus continuous vancomycin infusion for the treatment of late-onset sepsis in preterm infants","volume":"8","author":"Demirel","year":"2015","journal-title":"J. Neonatal Perinatal Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/jpids\/piy032","article-title":"Experience with continuous infusion vancomycin dosing in a large pediatric hospital","volume":"8","author":"Hurst","year":"2019","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/jac\/dky224","article-title":"Efficacy and safety of continuous infusions with elastomeric pumps for outpatient parenteral antimicrobial therapy (OPAT): An observational study","volume":"73","author":"Voumard","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1093\/jac\/dks328","article-title":"Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections","volume":"67","author":"Verrall","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","unstructured":"Mandell, G., Dolin, R., and Bennett, J. (2015). Principles and Practice of Infectious Diseases, Elsevier. [8th ed.]. Available online: https:\/\/www.sciencedirect.com\/book\/9781455748013\/mandell-douglas-and-bennetts-principles-and-practice-of-infectious-diseases."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/Pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: Critical interactions of \u2018bug and drug\u2019","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_43","first-page":"357","article-title":"Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy","volume":"2004","author":"Lodise","year":"2008","journal-title":"Chin. J. Infect. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated Pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","article-title":"Surviving Sepsis Campaign","volume":"45","author":"Rhodes","year":"2017","journal-title":"Crit. Care Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"50","author":"Solomkin","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_48","unstructured":"Bonkat, G., Pickard, R., Bartoletti, R., Bruy\u00e8re, F., Geerlings, S.E., Wagenlehner, F., and Wullt, B. (2019, June 14). EAU Guidelines on Urological Infections. Available online: https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-on-Urological-Infections-2018-large-text.pdf."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/jac\/dkx093","article-title":"Dose optimization of piperacillin\/tazobactam in critically ill children","volume":"72","author":"Willems","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jac\/dkh511","article-title":"The OPTAMA programme: Utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe","volume":"55","author":"Masterton","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/INF.0b013e3182a743c7","article-title":"Population pharmacokinetics of piperacillin\/tazobactam in critically ill young children","volume":"33","author":"Cies","year":"2014","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1128\/AAC.02089-15","article-title":"Population pharmacokinetics and pharmacodynamics of extended- infusion Piperacillin and Tazobactam in critically Ill children","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s00228-016-2131-0","article-title":"Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin\/tazobactam in neonates and young infants","volume":"72","author":"Chen","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.27654","article-title":"Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?","volume":"66","author":"Maarbjerg","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/pbc.22051","article-title":"Optimizing bactericidal exposure for \u03b2-lactams using prolonged and continuous infusions in the pediatric population","volume":"53","author":"Courter","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/INF.0b013e318298dfb8","article-title":"Optimization of continuous infusion of piperacillin-tazobactam in children with fever and neutropenia","volume":"32","author":"Mazingue","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Thibault, C., Lavigne, J., Litalien, C., Kassir, N., Th\u00e9or\u00eat, Y., and Autmizguine, J. (2019). Population pharmacokinetics and safety of Piperacillin-Tazobactam extended infusions in infants and children. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.01260-19"},{"key":"ref_58","first-page":"10","article-title":"Piperacillin\/Tazobactam in continuous infusion versus intermittent infusion in children with febrile neutropenia","volume":"71","year":"2019","journal-title":"Rev. Investig. Cl\u00edn."},{"key":"ref_59","first-page":"212","article-title":"Extended infusion of Piperacillin\/Tazobactam in children","volume":"22","author":"Knoderer","year":"2017","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_60","unstructured":"Kimberlin, D.W., Brady, M.T., Jackson, M.A., and Long, S.A.E. (2015). Red Book: 2015 Report of the Committee on Infectious Diseases, Elk Grove Village IAA of P. [30th ed.]."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1086\/425368","article-title":"Practice Guidelines for the Management of Bacterial Meningitis","volume":"39","author":"Tunkel","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00003495-199549040-00008","article-title":"Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy","volume":"49","author":"Rains","year":"1995","journal-title":"Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S0140-6736(89)90164-5","article-title":"Continuous infusion of ceftazidime in cystic fibrosis","volume":"1","author":"David","year":"1989","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1093\/jac\/dkz065","article-title":"Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: Implications for target attainment for empirical treatment against Pseudomonas aeruginosa","volume":"74","author":"Cojutti","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/00043426-200212000-00006","article-title":"Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer","volume":"24","author":"Dalle","year":"2002","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/PL00008370","article-title":"Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children","volume":"159","author":"Rappaz","year":"2000","journal-title":"Eur. J. Pediatr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1128\/AAC.00174-09","article-title":"Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis","volume":"53","author":"Hubert","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/ajhp\/zxy035","article-title":"Ceftazidime stability and pyridine toxicity during continuous i.v. infusion","volume":"76","author":"Jones","year":"2019","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_69","unstructured":"Johns Hopkins (2019). Johns Hopkins Antibiotics Guide, Unbound Medicine."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00006454-200103000-00032","article-title":"Review of the pharmacokinetics of cefepime in children","volume":"20","author":"Blumer","year":"2001","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1128\/AAC.02592-15","article-title":"Population pharmacokinetic assessment and pharmacodynamic implications of pediatric cefepime dosing for susceptible-dose-dependent organisms","volume":"60","author":"Shoji","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/1060028014566447","article-title":"Implementing extended-infusion Cefepime as standard of care in a children\u2019s hospital: A prospective descriptive study","volume":"49","author":"Nichols","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1093\/clinids\/24.Supplement_2.S181","article-title":"Penetration of meropenem in plasma and abdominal tissues from patients undergoing intraabdominal surgery","volume":"24","author":"Condon","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/INF.0b013e318170f8d2","article-title":"Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate","volume":"27","author":"Bradley","year":"2008","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_75","first-page":"32","article-title":"Use of meropenem in the treatment of severe infections in newborns","volume":"43","author":"Yatsyk","year":"1998","journal-title":"Antibiot. Chemoterapy"},{"key":"ref_76","unstructured":"Bradley, J.S., Nelson, J.D., Barnett, E.D., Cantey, J.B., Kimberlin, D.W., Palumbo, P.E., Sauberan, J., Howard Smart, J., and Steinbach, W.J. (2017). Nelson\u2019s Pediatric Antimicrobial Therapy, American Academy of Pediatrics. [23rd ed.]."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/ppul.22655","article-title":"Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems","volume":"47","author":"Zobell","year":"2012","journal-title":"Pediatr. Pulmonol."},{"key":"ref_78","unstructured":"(2019, November 18). Surveillance of Antimicrobial Resistance in Europe 2018. Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2018."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12427","article-title":"ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients","volume":"20","author":"Tacconelli","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/jac\/dkq044","article-title":"Stability of meropenem and doripenem solutions for administration by continuous infusion","volume":"65","author":"Berthoin","year":"2010","journal-title":"J. Antimicrob. Chemother. Engl."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ajhp\/54.4.412","article-title":"Stability of meropenem in intravenous solutions","volume":"54","author":"Patel","year":"1997","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_82","first-page":"479","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect. Dis. Clin."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1086\/344653","article-title":"Prevention of resistance: A goal for dose selection for antimicrobial agents","volume":"36","author":"Drusano","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0149-2918(04)80001-8","article-title":"Optimizing antimicrobial pharmacodynamics: Dosage strategies for meropenem","volume":"26","author":"Mattoes","year":"2004","journal-title":"Clin. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1128\/AAC.00351-09","article-title":"Meropenem pharmacokinetics in the newborn","volume":"53","author":"Pokorna","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/jac\/dkv289","article-title":"Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis","volume":"71","author":"Pettit","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_87","first-page":"276","article-title":"Population pharmacokinetics and pharmacodynamic target attainment of meropenem in critically ill young children","volume":"22","author":"Cies","year":"2017","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00228-019-02761-7","article-title":"Population pharmacokinetics of meropenem in critically ill children with different renal functions","volume":"76","author":"Rapp","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/INF.0000000000001445","article-title":"Conventional versus prolonged infusion of Meropenem in neonates with gram-negative late-onset Sepsis","volume":"36","author":"Shabaan","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1128\/AAC.00655-12","article-title":"Short versus long infusion of Meropenem in Very-Low-Birth-Weight neonates","volume":"56","author":"Padari","year":"2012","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/6\/329\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:39:54Z","timestamp":1760175594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/6\/329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":90,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["antibiotics9060329"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics9060329","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,17]]}}}